The Short Answer Educational content only. Not medical advice. Medication decisions require prescribing clinician evaluation. Discuss risks, benefits, drug interactions, and side effects with your treating provider before starting any medication. Memantine helps post-concussion cognition through NMDA receptor antagonism, addressing excitotoxicity and cognitive symptoms (Silverberg et al., 2020). Memantine (Namenda) is FDA-approved for moderate-to-severe Alzheimer's disease. Used off-label for post-traumatic brain injury cognitive symptoms and post-concussion syndrome. Typical dose ranges from 5-20 mg daily. Memantine is generally well-tolerated with few drug interactions. Emerging evidence supports memantine in TBI populations for cognitive symptoms. Mechanism addresses glutamate excitotoxicity thought to contribute to post-concussion cognitive dysfunction. Prescribing neurologist, physiatrist, or rehabilitation physician evaluation required. Memantine addresses NMDA excitotoxicity in PCS. Addresses NMDA excitotoxicity. Off-label for post-concussion cognition. Off-label PCS use. Generally well-tolerated. Generally well-tolerated. How Memantine Works Uncompetitive NMDA receptor antagonism. Uncompetitive NMDA antagonism. Blocks pathological glutamate signaling. Blocks pathological glutamate signaling. Preserves physiological glutamate signaling. Preserves physiological glutamate signaling. Reduces excitotoxicity. Reduces excitotoxicity. Neuroprotective effects proposed. Neuroprotective effects proposed. Voltage-dependent binding. Voltage-dependent binding. Fast off-rate kinetics. Fast off-rate kinetics. Cognitive protective effects. Cognitive protective effects. Post-Concussion Uses Post-TBI cognitive symptoms. Post-TBI cognitive symptoms. Post-concussion cognitive symptoms. Post-concussion cognitive symptoms. Memory difficulties. Memory difficulties. Attention difficulties. Attention difficulties. Executive function difficulties. Executive function difficulties. Processing speed reduction. Processing speed reduction. Word-finding difficulty. Word-finding difficulty. Chronic PCS cognitive symptoms. Chronic PCS cognitive symptoms. Adjunctive to cognitive rehabilitation. Adjunctive to cognitive rehabilitation. Evidence for Memantine in TBI and PCS FDA-approved for Alzheimer's disease. FDA-approved for Alzheimer's. Silverberg et al. (2020) guidelines mention NMDA antagonists. Silverberg guidelines mention. Small trials support post-TBI cognitive benefit. Small trials support post-TBI cognitive. Case series support PCS use. Case series support PCS. Preclinical evidence supports. Preclinical evidence supports. Larger trials needed. Larger trials needed. Neuroprotective mechanism theoretically attractive. Neuroprotective mechanism theoretically attractive. Typical Dosing for PCS Starting dose 5 mg daily. Starting dose 5 mg daily. Titration weekly. Titration weekly. Target dose 10 mg twice daily. Target dose 10 mg BID. Maximum dose 20 mg daily. Maximum dose 20 mg daily. Extended-release 28 mg once daily. Extended-release 28 mg daily. Adequate trial 8-12 weeks. Adequate trial 8-12 weeks. Common Side Effects Dizziness. Dizziness. Headache. Headache. Confusion. Confusion. Constipation. Constipation. Fatigue. Fatigue. Somnolence. Somnolence. Weight gain. Weight gain. Nausea. Nausea. Vomiting. Vomiting. Hypertension. Hypertension. Back pain. Back pain. Serious Side Effects Hallucinations rare. Hallucinations rare. Seizures rare. Seizures rare. Heart failure rare. Heart failure rare. Stroke rare. Stroke rare. Contraindications and Cautions Severe kidney impairment (dose adjustment). Severe kidney impairment dose adjustment. Seizure disorder caution. Seizure disorder caution. Severe hepatic impairment caution. Severe hepatic impairment caution. Urinary alkalinization affects clearance. Urinary alkalinization affects clearance. Cardiovascular disease caution. Cardiovascular disease caution. Pregnancy category B. Pregnancy category B. Drug Interactions Amantadine interaction. Amantadine interaction. Dextromethorphan interaction. Dextromethorphan interaction. Ketamine interaction. Ketamine interaction. Urinary alkalinizing agents (sodium bicarbonate). Urinary alkalinizing agents. Hydrochlorothiazide interaction. Hydrochlorothiazide interaction. Cimetidine, nicotine, quinidine minor interactions. Cimetidine nicotine quinidine minor interactions. Comparison to Other Cognitive-Enhancing Medications Cholinesterase inhibitors (donepezil, rivastigmine, galantamine). Cholinesterase inhibitors. Amantadine (NMDA antagonist plus dopamine). Amantadine NMDA plus dopamine. Modafinil (activating cognitive enhancer). Modafinil activating. Methylphenidate (stimulant). Methylphenidate stimulant. Memantine adjunctive to cholinesterase inhibitors in dementia. Memantine adjunctive in dementia. Memantine better tolerated than stimulants. Memantine better tolerated than stimulants. Special PCS Considerations Chronic PCS cognitive symptoms most studied indication. Chronic PCS cognitive symptoms most studied. Slow titration reduces side effects. Slow titration reduces side effects. Cognitive rehabilitation adjunctive. Cognitive rehabilitation adjunctive. Neuropsychological testing supports monitoring. Neuropsychological testing supports monitoring. Combination with amantadine caution. Combination with amantadine caution. Response variable in PCS populations. Response variable in PCS. Monitoring During Treatment Cognitive symptom monitoring. Cognitive symptom monitoring. Kidney function monitoring. Kidney function monitoring. Blood pressure monitoring. Blood pressure monitoring. Weight monitoring. Weight monitoring. Confusion monitoring. Confusion monitoring. Response evaluation every 3 months. Response evaluation every 3 months. Discontinuation Gradual taper over 1-2 weeks. Gradual taper over 1-2 weeks. Cognitive rebound possible. Cognitive rebound possible. Withdrawal syndrome not typical. Withdrawal syndrome not typical. Taper under prescriber guidance. Taper under prescriber guidance. Alternatives if Memantine Not Effective Amantadine. Amantadine. Modafinil. Modafinil. Methylphenidate. Methylphenidate. Atomoxetine. Atomoxetine. Donepezil (off-label for TBI cognitive symptoms). Donepezil off-label TBI cognitive. Cognitive rehabilitation. Cognitive rehabilitation. Neurofeedback. Neurofeedback. Cost and Insurance Generic memantine available. Generic memantine available. Extended-release brand more expensive. Extended-release brand more expensive. Insurance coverage variable for off-label use. Insurance coverage variable off-label. Prior authorization sometimes required. Prior authorization sometimes required. Alzheimer's diagnosis supports coverage. Alzheimer's diagnosis supports coverage. Off-label PCS coverage limited. Off-label PCS coverage limited. Supporting Mobility Routine These exercises complement memantine through cervical mobility and nervous system regulation. JME 155 Diaphragmatic breathing supports vagal tone and parasympathetic regulation during concussion recovery. 10 breaths every 60-90 minutes. JME 14 Chin tucks reduce upper cervical tension common in concussion injury. 10 repetitions with 5-second holds. JME 1 Cervical rotation supports cerebral blood flow and nervous system regulation. 10 repetitions each direction. JME 150 Thoracic rotation restores breathing depth shallow during concussion recovery. 8 repetitions per direction. Start your 3-day free trial for joint-specific mobility programs that support nervous system regulation through concussion recovery. Common Mistakes About Memantine for PCS Expecting rapid cognitive improvement. Effects gradual over weeks. Not combining with cognitive rehabilitation. Combined treatment better. Rapid titration causing side effects. Slow titration essential. Combined with amantadine without caution. Combined with amantadine caution. Not adjusting for kidney function. Kidney function affects dosing. How long does memantine take to work for post-concussion cognitive symptoms? Memantine typically takes 4-8 weeks for cognitive benefit. Effects gradual and subtle. Adequate trial 8-12 weeks before determining effectiveness. Combined with cognitive rehabilitation shows greater benefit. Neuropsychological testing supports monitoring. Response variable in post-concussion populations. Is memantine FDA-approved for concussion? No, memantine is FDA-approved for moderate-to-severe Alzheimer's disease only. Use for post-concussion syndrome and TBI is off-label. Emerging evidence supports use in TBI populations. Small trials and case series support use. Larger trials needed. Off-label prescribing common in specialized concussion care. Can I combine memantine with amantadine for PCS? Combining memantine with amantadine requires caution due to overlapping NMDA antagonism. Some prescribers combine at low doses for chronic PCS cognitive symptoms. Discuss with prescriber. Monitor for confusion, hallucinations, and side effects. Combined use not standard. Individual assessment determines appropriateness. Does insurance cover memantine for post-concussion syndrome? Insurance coverage limited for off-label PCS use. Coverage typically requires Alzheimer's diagnosis. Prior authorization often required for other indications. Generic memantine affordable if cash pay. Extended-release brand more expensive. Discuss coverage with pharmacy and prescriber. Cost may influence treatment decisions. What is the difference between memantine and cholinesterase inhibitors for PCS? Memantine works through NMDA receptor antagonism reducing excitotoxicity. Cholinesterase inhibitors (donepezil, rivastigmine, galantamine) increase acetylcholine. Different mechanisms. Sometimes combined in Alzheimer's. Memantine better tolerated in TBI populations. Cholinesterase inhibitors may cause GI side effects. Both used off-label for PCS cognitive symptoms. References Patricios, J. S., et al. (2023). Consensus statement on concussion in sport: the 6th International Conference on Concussion in Sport, Amsterdam, October 2022. British Journal of Sports Medicine, 57(11), 695-711. PubMed Silverberg, N. D., et al. (2020). Management of concussion and mild traumatic brain injury: a synthesis of practice guidelines. Archives of Physical Medicine and Rehabilitation, 101(2), 382-393. PubMed